8-K: Kintara Therapeutics and TuHURA Biosciences Announce Merger, Providing Financial Details

Kintara Therapeutics and TuHURA Biosciences are merging, with TuHURA surviving as a wholly-owned subsidiary of Kintara, and this report provides unaudited financial statements for TuHURA and pro forma financials for the combined entity.

Summary

• Kintara Therapeutics and TuHURA Biosciences have entered into a merger agreement, where TuHURA will become a wholly-owned subsidiary of Kintara.
• This report includes unaudited financial statements for TuHURA as of June 30, 2024, and for the six months ended June 30, 2024 and 2023.
• It also provides unaudited pro forma financial information for the combined company as of June 30, 2024, and for the year ended December 31, 2023.
• The merger is expected to be accounted for as a reverse recapitalization, with TuHURA treated as the accounting acquirer.
• TuHURA's cash and cash equivalents were $12.3 million as of June 30, 2024, while Kintara's were $4.9 million.
• TuHURA's net loss for the six months ended June 30, 2024, was $10.1 million, compared to a net loss of $22.1 million for the same period in 2023.
• The pro forma combined net loss for the six months ended June 30, 2024, is $12.5 million.
• The pro forma combined net loss for the year ended December 31, 2023, is $48.7 million.
• The combined company will focus on TuHURA's operations and in-process research and development assets.
• Kintara's CEO will not be part of the management team of the surviving company.
• The merger is expected to close in the fourth quarter of 2024.
• The combined company shares are expected to trade on NASDAQ under the symbol HURA.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the merger and acquisition of Kineta's asset are positive developments, the significant financial losses and going concern issues for TuHURA temper the overall sentiment. The pro forma combined losses also indicate a challenging financial outlook.

Positives

• The merger combines the expertise and resources of Kintara and TuHURA to advance a diversified oncology pipeline.
• TuHURA has a strong cash position of $12.3 million as of June 30, 2024.
• TuHURA is progressing with its clinical trials, including a Phase II trial for Merkel cell carcinoma expected to begin in the second half of 2024.
• The combined company will focus on TuHURA's operations and in-process research and development assets.
• TuHURA has secured an exclusivity agreement with Kineta for a promising anti-VISTA antibody.

Negatives

• TuHURA has incurred significant net losses, with a $10.1 million loss for the six months ended June 30, 2024.
• The pro forma combined company also shows substantial losses, with a $12.5 million loss for the six months ended June 30, 2024, and a $48.7 million loss for the year ended December 31, 2023.
• There is substantial doubt about TuHURA's ability to continue as a going concern for the next 12 months.
• Kintara's CEO will not be part of the management team of the surviving company.
• The combined company anticipates no significant value derived from any in-process research and development assets of Kintara as of the Merger.

Risks

• The merger is subject to various conditions, including Kintara stockholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• The combined company may face challenges in estimating operating expenses and merger-related costs.
• The merger could be terminated due to various events or circumstances.
• The merger may negatively impact business relationships and operating results.
• The combined company may face legal proceedings related to the merger.
• There are risks related to protecting intellectual property rights and competitive responses to the merger.
• The combined company may face unexpected costs, charges, or expenses.
• The success of the combined business is not guaranteed.
• The company is subject to legislative, regulatory, political, and economic developments.
• There is substantial doubt about TuHURA's ability to continue as a going concern for the next 12 months.

Future Outlook

The combined company will focus on advancing TuHURA's oncology pipeline, including its ImmuneFx platform and bi-functional antibody drug conjugates. The merger is expected to close in the fourth quarter of 2024, and the combined company shares are expected to trade on NASDAQ under the symbol HURA. TuHURA expects to raise cash through the sale of common shares, issuance of convertible notes, obtaining grants, or commercial partnerships.

Management Comments

• TuHURA's management has concluded that it is probable that the Milestone of the Kintara legacy clinical studies pursuant to the CVR Agreement will be achieved and the CVR Shares will be issued.
• TuHURA currently anticipates no significant value derived from any in-process research and development assets of Kintara as of the Merger.
• Kintara's chief executive officer is not an assumed employee of the surviving company and as such will not be a part of the assembled workforce of the surviving company following the closing of the Merger.

Industry Context

This merger reflects a trend in the biopharmaceutical industry where companies combine resources to advance their pipelines and achieve greater scale. The focus on immuno-oncology and antibody drug conjugates aligns with current areas of high interest and investment in the sector. The acquisition of Kineta's KVA12123 asset further demonstrates the company's strategic focus on innovative cancer therapies.

Comparison to Industry Standards

• The merger between Kintara and TuHURA is similar to other mergers in the biotech industry where smaller companies combine to gain scale and resources.
• TuHURA's focus on immuno-oncology and antibody drug conjugates is in line with current industry trends, with companies like Bristol Myers Squibb and Merck also heavily invested in these areas.
• The financial losses reported by TuHURA are not uncommon for clinical-stage biotech companies, which often require significant investment in research and development before generating revenue.
• The pro forma combined losses are also typical for companies in this stage of development, with similar companies like Adaptimmune and Iovance also reporting significant losses.
• The cash position of $12.3 million for TuHURA is relatively low for a company planning to conduct multiple clinical trials, and further capital raises will likely be required, similar to other companies in the sector.

Stakeholder Impact

• Shareholders of Kintara and TuHURA will be impacted by the merger, with TuHURA shareholders owning the majority of the combined company.
• Employees of both companies will be affected by the merger, with Kintara's CEO not being part of the management team of the surviving company.
• Customers and partners of both companies will need to adapt to the new combined entity.
• Creditors of both companies will be impacted by the merger, with the combined entity assuming the liabilities of both companies.

Next Steps

• The merger is expected to close in the fourth quarter of 2024.
• The combined company will need to meet the initial listing requirements to maintain its listing on the Nasdaq Capital Market.
• TuHURA will continue its due diligence on the KVA12123 asset from Kineta.
• The combined company will need to integrate the operations of Kintara and TuHURA.
• TuHURA will need to secure additional funding to support its clinical development programs.

Key Dates

Keywords

merger, Kintara Therapeutics, TuHURA Biosciences, immuno-oncology, clinical trials, financial statements, pro forma, reverse recapitalization, convertible notes, NASDAQ, oncology, biopharmaceutical